Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014; 129:837-847.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013; 112:1142-1147.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006; 27:949-953.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110:1042-1046.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34:2746-2751.
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6:213-220.
Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke 2013; 44:3103-3108.
Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015; 4:e001486.
McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation 2012; 126:e143-146.
Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167:1807-1824.
Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 82:2N-9N.
Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol 2013; 167:2412-2420.
Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P et al. RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: The RE-LY Atrial Fibrillation Registry. Circulation 2014; 129:1568-1576.
Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: Insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012; 5:632-639.
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107:2920-2925.
Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: A systematic review and meta-analysis. Stroke 2014; 45:520-526.
Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA et al. CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370:2478-2486.
Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet 2015; 386:154-162.
Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98:946-952.
Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359-364.
Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N. All-cause mortality in 272, 186 patients hospitalized with incident atrial fibrillation 1995-2008: A Swedish nationwide long-term case-control study. Eur Heart J 2013; 34:1061-1067.
Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: An individualpatient data meta-analysis. Lancet 2014; 384:2235-2243.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22:983-988.
Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98:476-484.
Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2012; 7:276-281.
Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: A prospective multicenter cohort study. Stroke 2013; 44:3357-3364.
Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28:316-321.
Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29:2125-2132.
Ball J, Carrington MJ, Stewart S. SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: A forgotten component of clinical management?. Heart 2013; 99:542-547.
Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J. Increased risk of cognitive and functional decline in patients with atrial fibrillation: Results of the ONTARGET and TRANSCEND studies. CMAJ 2012; 184: E329-336.
Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: A systematic review. Am J Med 2006; 119:448.e1-19.
von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: A longitudinal analysis- data from the German Competence Network on Atrial Fibrillation. Europace 2015; 17:1354-1362.
Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2014; 167:735-742.e2.
Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K. Management of patients wtih atrial fibrillation by primary care physicians in Germany: 1-year results of the ATRIUM registry. Clin Cardiol 2014; 37: 277-284.
Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart 2004; 90:286-292.
Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011; 4:313-320.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A metaanalysis of randomised trials. Lancet 2014; 383:955-962.
Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166:442-448.
Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med 2014; 160:760-773.
Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35:3365-3376.
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M et al. RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: A competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013; 128:2192-2201.
Senoo K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 2015; 46:2523-2528.
Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014; 174:107-114.
Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: Systematic review and meta-analysis of cohort studies. BMJ 2016; 532:h7013.
Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: Epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016; 13:321-332.
Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 9519 patients. Int J Cardiol 2014; 177:91-99.
Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112:1687-1691.
Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113:485-490.
Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: The Belgrade atrial fibrillation study. Int J Cardiol 2012; 161:39-44.
Ball J, Carrington MJ, Wood KA, Stewart S. SAFETY Investigators. Women versus men with chronic atrial fibrillation: Insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). PLoS One 2013; 8:e65795.
Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: A systematic review. QJM 2007; 100:599-607.
Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J et al. Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol 2009; 32:622-626.
Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V et al. Gender-related differences in catheter ablation of atrial fibrillation. Europace 2007; 9:613-620.
Henry L, Hunt S, Holmes SD, Martin LM, Ad N. Are there gender differences in outcomes after the Cox-Maze procedure for atrial fibrillation?. Innovations (Phila) 2013; 8:190-198.
Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: Ten years later. Gend Med 2010; 7:206-217.
Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004; 291:2851-2855.
Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP et al. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol 2012; 60:917-921.
Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012; 44:670-675.
Olesen MS, Nielsen MW, Haunso S, Svendsen JH. Atrial fibrillation: The role of common and rare genetic variants. Eur J Hum Genet 2014; 22: 297-306.
Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S et al. METASTROKE Consortium, AFGen Consortium, Benjamin EJ, Milan DJ, Melander O, Heckbert SR, Ford I, Liu Y et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation 2014; 130:1225-1235.
Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448:353-357.
Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G et al. Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol 2014; 63:1200-1210.
Lemmens R, Buysschaert I, Geelen V, Fernandez-Cadenas I, Montaner J, Schmidt H et al. International Stroke Genetics Consortium. The association of the 4q25 susceptibility variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke 2010; 41:1850-1857.
Tada H, Shiffman D, Smith JG, Sjogren M, Lubitz SA, Ellinor PT et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2014; 45:2856-2862.
Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting leftsided pacemaker specification. Proc Natl Acad Sci U S A 2010; 107:9753-9758.
Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A. Modulation of conductive elements by Pitx2 and their impact on atrial arrhythmogenesis. Cardiovasc Res 2011; 91:223-231.
Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH et al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 2011; 4:123-133.
Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB et al. Pitx2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial fibrillation. Proc Natl Acad Sci U S A 2014; 111: 9181-9186.
Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010; 55:747-753.
Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm 2013; 10: 849-855.
Benjamin Shoemaker M, Muhammad R, Parvez B, White BW, Streur M, Song Y et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm 2013; 10:394-400.
Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield T et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012; 60:539-545.
Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H et al. ESC CRT R&D and European Affairs Work Shop on Personalized Medicine. The continuum of personalized cardiovascular medicine: A position paper of the European Society of Cardiology. Eur Heart J 2014; 35:3250-3257.
Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013; 15: 1540-1556.
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al. Heart Rhythm Society, European Heart Rhythm Association. HRS/ EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13: 1077-1109.
Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005; 67:655-666.
Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of human atrial fibrillation. Biomed Pharmacother 2010; 64:177-183.
Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm 2009; 6:454-460.
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-1184.
Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013; 36: 795-805a.
Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C et al. Atrial amyloidosis: An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106:2091-2097.
Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation 2001; 103:691-698.
Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: Longitudinal dissociation. Circ Arrhythm Electrophysiol 2010; 3:606-615.
Spach MS, Josephson ME. Initiating reentry: The role of nonuniform anisotropy in small circuits. J Cardiovasc Electrophysiol 1994; 5:182-209.
Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002; 105:2672-2678.
Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: Impact of rate and rhythm. J Am Coll Cardiol 2013; 61:852-860.
Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: A clinical review. Eur Heart J 2013; 34:1475-1480.
Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109:363-368.
Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18:1076-1082.
Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014; 102:205-213.
Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004; 25:1237-1241.
Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T et al. The G protein-gated potassium current I(K, ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005; 112: 3697-3706.
Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999; 85:428-436.
Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011; 91:265-325.
Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 2014; 129:145-156.
Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 2012; 125:2059-2070.
Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol 2001; 38: 883-891.
Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999; 34:1577-1586.
Spach MS, Heidlage JF, Barr RC, Dolber PC. Cell size and communication: Role in structural and electrical development and remodeling of the heart. Heart Rhythm 2004; 1:500-515.
Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol 2008; 51:2053-2057.
Barretto AC, Mady C, Nussbacher A, Ianni BM, Oliveira SA, Jatene A. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998; 67:19-25.
Levy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:2670-2674.
Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy. Circ Res 2014; 114:1500-1515.
Christ T, Rozmaritsa N, Engel A, Berk E, Knaut M, Metzner K et al. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc Natl Acad Sci U S A 2014; 111: 11193-11198.
Greiser M, Kerfant BG, Williams GS, Voigt N, Harks E, Dibb KM et al. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 2014; 124:4759-4772.
Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ et al. Spontaneous pulmonary vein firing in man: Relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J Cardiovasc Electrophysiol 2007; 18:1067-1075.
Atienza F, Almendral J, Moreno J, Vaidyanathan R, Talkachou A, Kalifa J et al. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: Evidence for a reentrant mechanism. Circulation 2006; 114:2434-2442.
Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000; 101:194-199.
Sahadevan J, Ryu K, Peltz L, Khrestian CM, Stewart RW, Markowitz AH. Epicardial mapping of chronic atrial fibrillation in patients: Preliminary observations. Circulation 2004; 110:3293-3299.
Sanders P, Nalliah CJ, Dubois R, Takahashi Y, Hocini M, Rotter M et al. Frequency mapping of the pulmonary veins in paroxysmal versus permanent atrial fibrillation. J Cardiovasc Electrophysiol 2006; 17:965-972.
Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959; 58:59-70.
Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-426.
Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012; 60: 628-636.
Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S et al. Driver domains in persistent atrial fibrillation. Circulation 2014; 130:530-538.
Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T et al. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J 2004; 25:1385-1394.
Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C. Perception of atrial fibrillation before and after radiofrequency catheter ablation: Relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112:307-313.
Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: Executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30: 2969-2977c.
Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 2015; 191:172-177.
Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: Prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4:369-382.
Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: Report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31:967-975.
Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: Analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36:281-287a.
Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: Results from the ROCKET-AF Trial. Eur Heart J 2015; 36:288-296.
Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial. BMJ 2007; 335:383.
Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012; 43:2689-2694.
Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J et al. EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370:2467-2477.
Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013; 15:135-140.
Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY. Prevalence of atrial fibrillation in the general population and in high-risk groups: The ECHOES study. Europace 2012; 14:1553-1559.
Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005; 9:iii-iv, ix-x, 1-74.
Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 2015; 17:1023-1029.
Levin LA, Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace 2015; 17:207-214.
Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110:213-222.
Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: Implications for stroke prevention. Circulation 2013; 127:930-937.
Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A et al. Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 2009; 11:1362-1368.
Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 2014; 16:1291-1295.
Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med 2014; 127:95.e11-97.
Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111:1167-1176.
Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community. Curr Opin Cardiol 2014; 29:28-35.
Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120-129.
Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation - results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3:141-147.
Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C et al. ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014; 129:2094-2099.
Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M et al. Device-detected atrial fibrillation and risk for stroke: An analysis of >10, 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014; 35:508-516.
Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L et al. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 2011; 57:167-172.
Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS. Heart Rhythm 2011; 8:1416-1423.
Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ Arrhythm Electrophysiol 2009; 2:474-480.
Lamas G. How much atrial fibrillation is too much atrial fibrillation?. N Engl J Med 2012; 366:178-180.
Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012; 14:8-27.
Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106:1012-1019.
Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: A systematic review and meta-analysis. Lancet Neurol 2015; 14:377-387.
Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology 2016; 86:261-269.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol 2014; 13:429-438.
Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: Analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ 2007; 335:380.
Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004; 43:47-52.
Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation 2015; 131:2176-2184.
Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: More than just one of a kind. Eur Heart J 2015; 36:2356-2363.
Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242-2246.
Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK et al. The natural history of lone atrial flutter. Ann Intern Med 2004; 140: 265-268.
Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007; 115: 3050-3056.
Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation following DDDR pacemaker implantation. Am J Cardiol 2000; 85: 1445-1450.
Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: Insights from 1, 195 patients continuously monitored with implantable devices. J Am Coll Cardiol 2014; 63:2840-2848.
Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY. Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. Int J Cardiol 2013; 167:2682-2687.
Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: State of the art. Lancet 2012; 380:1509-1519.
Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM et al. Lone atrial fibrillation: Does it exist?. J Am Coll Cardiol 2014; 63: 1715-1723.
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: Relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114:1453-1468.
Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010; 106:1615-1620.
Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K et al. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: Insights from the Danish Diet, Cancer, and Health study. Chest 2014; 145:559-566.
Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013; 99: 1093-1099.
Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011; 57:831-838.
Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA et al. The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation. J Am Coll Cardiol 2013; 62:2205-2214.
Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. JAMA 2014; 311:498-506.
Bonizzi P, Zeemering S, Karel JM, Di Marco LY, Uldry L, Van Zaen J et al. Systematic comparison of non-invasive measures for the assessment of atrial fibrillation complexity: A step forward towards standardization of atrial fibrillation electrogram analysis. Europace 2014; 17:318-325.
Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G et al. A roadmap to improve the quality of atrial fibrillation management: Proceedings from the fifth Atrial Fibrillation Network/ European Heart Rhythm Association consensus conference. Europace 2016; 18:37-50.
Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: A roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol 2016; 13:230-237.
Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36:1303-1309.
Sears SF, Serber ER, Alvarez LG, Schwartzman DS, Hoyt RH, Ujhelyi MR. Understanding atrial symptom reports: Objective versus subjective predictors. Pacing Clin Electrophysiol 2005; 28:801-807.
Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol 2010; 63:1402-1409.
Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H et al. RealiseAF investigators. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: Data from the RealiseAF cross-sectional international registry. Heart 2012; 98: 195-201.
Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Pharmacological Intervention in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 2003; 24:1430-1436.
Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: A systematic review of randomized and nonrandomized trials. Clin Med Insights Cardiol 2013; 7:1-20.
Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG et al. RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43:241-247.
Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 2003; 41:1697-1702.
Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61:1894-1903.
Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF et al. Symptoms and functional status of patients with atrial fibrillation: State of the art and future research opportunities. Circulation 2012; 125: 2933-2943.
Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramirez P, Badia X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 2010; 12:364-370.
Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR et al. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4:15-25.
Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR et al. Interpreting changes in quality of life in atrial fibrillation: How much change is meaningful?. Am Heart J 2013; 166:381-387.e8.
Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51:903-912.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20:1727-1736.
Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: Executive summary. Eur Heart J 2007; 28:2803-2817.
Dorian P, Cvitkovic SS, Kerr CR, Crystal E, Gillis AM, Guerra PG et al. A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF scale. Can J Cardiol 2006; 22:383-386.
Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16:6-14.
Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: A report from the EORP-AF General Pilot Registry. Europace 2015; 17:1777-1786.
Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 2015; 8: 393-402.
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: Clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015; 128:509-518 e2.
Szymanski FM, Filipiak KJ, Karpinski G, Platek AE, Opolski G. Occurrence of poor sleep quality in atrial fibrillation patients according to the EHRA score. Acta Cardiol 2014; 69:291-296.
Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P. The European Heart Rhythm Association symptom classification for atrial fibrillation: Validation and improvement through a simple modification. Europace 2014; 16:965-972.
Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P. ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: Baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100:897-905.
Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009; 11: 423-434.
von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M et al. Depression in paroxysmal and persistent atrial fibrillation patients: A cross-sectional comparison of patients enroled in two large clinical trials. Europace 2014; 16:812-819.
Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol 2014; 64:2222-2231.
Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA 2013; 310:2050-2060.
Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455-2461.
Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: A large population cohort study. BMJ 2012; 345:e7895.
Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J 2014; 167:123-126
Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the netherlands. J Am Coll Cardiol 2015; 66:1000-1007.
Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003; 21:1012-1016.
Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49:565-571.
Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011; 4:26-32.
Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M et al. Smoking and incidence of atrial fibrillation: Results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 2011; 8:1160-1166.
Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: A prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014; 64:281-289.
Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009; 103:1572-1577.
Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 2013; 9:123-127.
Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure?. Europace 2011; 13:ii13-17.
Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health 2012; 15:240-248.
Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do?. Eur Heart J 2015; 36:3250-3257.
Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47:1997-2004.
Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016; 203:660-666.
Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009; 11:676-683.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. The Task Force for the diagnosis and teatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J; doi:10.1093/eurheartj/ehw128. Published online ahead of print 20 May 2016.
Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016; 18:12-36.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY et al. Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351:h4451.
Anselmino M, Matta M, D'Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: A systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014; 7:1011-1018.
Ganesan AN, Nandal S, Luker J, Pathak RK, Mahajan R, Twomey D et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: A systematic review of efficacy and effect on ejection fraction. Heart Lung Circ 2015; 24:270-280.
Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359:1778-1785.
Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: Pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014; 172:40-46.
Kusunose K, Yamada H, Nishio S, Tomita N, Niki T, Yamaguchi K et al. Clinical utility of single-beat E/e' obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging 2009; 2:1147-1156.
Li C, Zhang J, Zhou C, Huang L, Tang H, Rao L. Will simultaneous measurement of E/e' index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-valvular atrial fibrillation?. Eur J Echocardiogr 2010; 11:296-301.
Senechal M, O'Connor K, Deblois J, Magne J, Dumesnil JG, Pibarot P et al. A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in patients with atrial fibrillation. Echocardiography 2008; 25:57-63.
Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 1999; 12:927-931.
Wada Y, Murata K, Tanaka T, Nose Y, Kihara C, Uchida K et al. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J 2012; 76:675-681.
Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015; 65:1668-1682.
Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299-2307.
Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45:1832-1839.
Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: A systematic review and meta-analysis. Am J Ther 2008; 15:36-43.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86-92.
GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360:1606-1617.
Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5:43-51.
Active I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364:928-938.
Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59:1598-1603.
Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35:1669-1677.
Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: A nationwide study. Eur Heart J 2014; 35:1205-1214.
Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719.
Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S et al. Hypertension and atrial fibrillation: Diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012; 30:239-252.
Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106:331-336.
Ueng K-C, Tsai T-P, Yu W-C, Tsai C-F, Lin M-C, Chan K-C et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24:2090-2098.
Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152:217-222.
Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007; 99:1544-1548.
Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74:236-241.
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451-2496.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2438-2488.
Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26:2422-2434.
Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B et al. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 2014; 114:1722-1728.
Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC et al. Influence of preoperative atrial fibrillation on late results of mitral repair: Is concomitant ablation justified?. Ann Thorac Surg 2007; 84: 434-442; discussion 442-433.
Ngaage DL, Schaff HV, Barnes SA, Sundt TM III, Mullany CJ, Dearani JA et al. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: Is there an argument for concomitant arrhythmia surgery?. Ann Thorac Surg 2006; 82:1392-1399.
Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N et al. Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 2005; 26:1866-1872.
Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W et al. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 2001; 104:I59-63.
Maan A, Heist EK, Passeri J, Inglessis I, Baker J, Ptaszek L et al. Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol 2015; 115:220-226.
Barbash IM, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M et al. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015; 85:468-477.
Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988; 19:937-941.
Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi A et al. Left atrial remodelling in mitral regurgitation-methodologic approach, physiological determinants, and outcome implications: A prospective quantitative Doppler-echocardiographic and electron beamcomputed tomographic study. Eur Heart J 2007; 28:1773-1781.
Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM et al. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. Int J Cardiol 2013; 168:4093-4097.
Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995; 74:261-267.
Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE et al. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: Reversal with arrhythmia control. J Am Coll Cardiol 2011; 58:1474-1481.
Kihara T, Gillinov AM, Takasaki K, Fukuda S, Song JM, Shiota M. Mitral regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: An echocardiographic study. Echocardiography 2009; 26:885-889.
Zhou X, Otsuji Y, Yoshifuku S, Yuasa T, Zhang H, Takasaki K et al. Impact of atrial fibrillation on tricuspid and mitral annular dilatation and valvular regurgitation. Circ J 2002; 66:913-916.
Ring L, Dutka DP, Wells FC, Fynn SP, Shapiro LM, Rana BS. Mechanisms of atrial mitral regurgitation: Insights using 3D transoesophageal echo. Eur Heart J Cardiovasc Imaging 2014; 15:500-508.
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H et al. ESC Committee for Practice Guidelines (CPG), Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012; 42:S1-44.
Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: Results of a physicians' survey. Europace 2014; 16:1720-1725.
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759.
Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. Br Med J 1964; 1:1209-1212.
De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation?. A reappraisal. Eur Heart J 2014; 35:3328-3335.
Goldstone AB, Patrick WL, Cohen JE, Aribeana CN, Popat R, Woo YJ. Early surgical intervention or watchful waiting for the management of asymptomatic mitral regurgitation: A systematic review and meta-analysis. Ann Cardiothorac Surg 2015; 4:220-229.
Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 2012; 60:1421-1428.
Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: Results of the ADVANCE study. Eur Heart J 2009; 30:1128-1135.
Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015; 29:88-92.
Olson TM, Terzic A. Human K(ATP) channelopathies: Diseases of metabolic homeostasis. Pflugers Arch 2010; 460:295-306.
Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104:2886-2891.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol 2015; 26:223-225.
Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014; 114:1217-1222.
Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke 2015; 46: 2168-2174.
Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: A population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014; 13:123.
Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: The Loire valley atrial fibrillation project. Chest 2015; 147:1103-1110.
Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY. Physical activity, obesity, weight change, and risk of atrial fibrillation: The Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014; 7:620-625.
Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006; 27:96-106.
Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 2008; 155:310-315.
Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471-2477.
Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013; 126:640.e649-617.
Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999; 83: 1242-1247.
Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL. Effect of obesity and overweight on left ventricular diastolic function: A communitybased study in an elderly cohort. J Am Coll Cardiol 2011; 57:1368-1374.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated Creactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-2135.
Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol 2015; 65:2159-2169.
Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015; 66:985-996.
Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation 2008; 117:2583-2590.
Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19:668-672.
Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of body mass index on atrial fibrillation recurrence: A meta-analysis of observational studies. Pacing Clin Electrophysiol 2013; 36:748-756.
Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and quality of life in atrial fibrillation patients after catheter ablation: A meta-analysis and systematic review. Clin Cardiol 2013; 36:269-275.
Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007; 50:234-242.
Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M et al. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2013; 111:368-373.
Vizzardi E, Sciatti E, Bonadei I, D'Aloia A, Curnis A, Metra M. Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc Med (Hagerstown) 2014, doi 10.2459/JCM.0000000000000043.
Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update. Curr Cardiol Rev 2012; 8:265-272.
Lin YK, Lai MS, Chen YC, Cheng CC, Huang JH, Chen SA et al. Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 2012; 122:121-132.
Linz D. Atrial fibrillation in obstructive sleep apnea: Atrial arrhythmogenic substrate of a different sort. Am J Cardiol 2012; 110:1071.
Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: The impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010; 3:445-451.
Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013; 62:300-305.
Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013; 10:331-337.
Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. J Am Heart Assoc 2013; 2: E000421.
Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: A metaanalysis of observational studies. Europace 2014; 16:1309-1314.
Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373:1095-1105.
Bitter T, Nolker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O. Predictors of recurrence in patients undergoing cryoballoon ablation for treatment of atrial fibrillation: The independent role of sleepdisordered breathing. J Cardiovasc Electrophysiol 2012; 23:18-25.
Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011; 108:47-51.
Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013; 29:S71-78.
Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013; 111:1159-1164.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-2104.
Page K, Marwick TH, Lee R, Grenfell R, Abhayaratna WP, Aggarwal A et al. A systematic approach to chronic heart failure care: A consensus statement. Med J Aust 2014; 201:146-150.
Stock S, Pitcavage JM, Simic D, Altin S, Graf C, Feng W. Chronic care model strategies in the United States and Germany deliver patient-centered, highquality diabetes care. Health Aff (Millwood) 2014; 33:1540-1548.
Lundstrom H, Siersma V, Nielsen AB, Brodersen J, Reventlow S, Andersen PK. The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: A 19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 2014; 57:1119-1123.
Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013; 34: 2725-2730.
Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996; 74:511-544.
Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A et al. Euro Heart Survey Investigators. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007; 153:1006-1012.
Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic conditions: The contribution of the ICCC Framework. Health Policy 2012; 105:55-64.
Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al. Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105:1010-1023.
Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R et al. Nurse-led care vs. usual care for patients with atrial fibrillation: Results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012; 33: 2692-2699.
Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 2013; 15:1128-1135.
Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: Pragmatic, multicentre, randomised controlled trial. Lancet 2015; 385:775-784.
Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidisciplinary atrial fibrillation clinic. Curr Cardiol Rev 2013; 9:55-62.
Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V et al. Clinical management of atrial fibrillation: Early interventions, observation, and structured follow-up reduce hospitalizations. Am J Emerg Med 2012; 30:1962-1969.
Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S et al. An Integrated Management Approach to Atrial Fibrillation. J Am Heart Assoc 2016; 5:e002950.
Peterson ED, Ho PM, Barton M, Beam C, Burgess LH, Casey DE Jr. et al. ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician-Patient Shared Accountability in Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation 2014; 130:1984-1994.
Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT et al. Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015; 17:1747-1769.
Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An integrated chronic care program for patients with atrial fibrillation: Study protocol and methodology for an ongoing prospective randomised controlled trial. Int J Nurs Stud 2010; 47:1310-1316.
Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M et al. EACVI/ EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging 2016; 17:355-383.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the american society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015; 16:233-271.
Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2015; 169:31-38.
Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108:3006-3010.
Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation 2009; 120:1768-1774.
Bartel T, Erbel R. Acute Trial Investigators. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J 2001; 22:2041-2044.
Mahnkopf C, Mitlacher M, Brachmann J. [Relevance of magnetic resonance imaging for catheter ablation of atrial fibrillation]. Herzschrittmacherther Elektrophysiol 2014; 25:252-257.
Haemers P, Claus P, Willems R. The use of cardiac magnetic resonance imaging in the diagnostic workup and treatment of atrial fibrillation. Cardiol Res Pract 2012; 2012:658937.
Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012; 60: 2402-2408.
Lewalter T, Ibrahim R, Albers B, Camm AJ. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace 2013; 15:652-656.
Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: Executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-2817.
Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: Protocol for a two-phase study. BMC Health Serv Res 2008; 8:221.
Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J et al. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. J Am Heart Assoc 2014; 3:e001179.
Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost 2015; 13:495-504.
Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147:590-592.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817.
Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. Heart Rhythm 2015; 12:e105-113.
Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111:833-841.
O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2014; 167:601-609.e1.
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3:624-631.
Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013; 6: 567-574.
Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125:773-778.
Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159:677-685.
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY. BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007; 370: 493-503.
Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY et al. AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11:225-231.
The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998; 279:1273-1277.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-943.
Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003; 290:1049-1056.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137:263-272.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. ESC Committee for Practice Guidelines, European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12:1360-1420.
Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, Camm AJ. Atrial fibrillation guidelines across the Atlantic: A comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013; 34:1471-1474.
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342:d124.
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015; 65:635-642.
Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015; 65: 1385-1394.
Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F et al. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest 2016; 149:960-968.
Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke 2016; 47:1364-1367.
Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015; 65:225-232.
Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114:826-834.
Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost 2012; 10:1745-1751.
Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation?. A systematic review and meta-analysis. QJM 2014; 107:955-967.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125:1605-1616.
Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61:2274-2284.
Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37: 1582-1590.
Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100.
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395-401.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510.
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW et al. ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: A derivation and validation study. Lancet 2016; 387:2302-2311.
O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE et al. The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36:3258-3264.
Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: An updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011; 90:1191-1200.
Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C et al. Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9:1460-1467.
Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79, 884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9:39-48.
Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013; 62:2199-2204.
Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M et al. ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 130:1847-1858.
Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012; 33:1886-1892.
Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015; 113: 1370-1377.
Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131:157-164.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT(2)R(2) score. Chest 2013; 144:1555-1563.
Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146:719-726.
Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127:1083-1088.
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206-1214.
Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015; 17:187-193.
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63: 2141-2147.
Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: The apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012; 43:3291-3297.
Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-1876.
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385:2288-2295.
Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: Results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS Investigators. XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37:1145-1153
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010; 376:975-983.
Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE et al. ROCKET AF Investigators. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: Results from the ROCKET AF trial. J Am Heart Assoc 2014; 3: E000521.
Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367:625-635.
Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-analysis. Stroke 2013; 44:1329-1336.
Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2599-2604.
Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J 2014:36:297-306.
Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: Population based observational study. BMJ 2015; 350:h246.
Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ, Packer DL. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. Am J Cardiol 2016; 117:69-75.
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17:1467-1507.
Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27:3816-3822.
Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57:1339-1348.
Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB et al. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77:1098-1106.
Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20:2223-2233.
Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011; 6:2662-2668.
Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129: 1196-1203.
Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: A nationwide observational cohort study. J Am Coll Cardiol 2014; 64:2471-2482.
Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131:972-979.
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129:961-970.
Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387-2394.
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Eur Heart J 2012; 33:2821-2830.
Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527-539.
Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106:739-749.
Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014; 16:631-638.
ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367:1903-1912.
Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029-2037.
Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators. Stroke 2009; 40:1410-1416.
Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24:349-357.
Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. J Am Coll Cardiol 2004; 44:1557-1566.
Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: Ten- and twenty-year perspectives. Ann Intern Med 1960; 52:741-749.
Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can Med Assoc J 1954; 71:323-331.
Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-valve replacement. N Engl J Med 1994; 330:507-508; author reply 508-509.
Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med 1998; 128:885-889.
Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008; 1:84-91.
Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124:37-41.
Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106:968-977.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110:1087-1107.
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127:634-640.
Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: A systematic review and analysis of observational studies. JACC Cardiovasc Interv 2014; 7:296-304.
Lewalter T, Kanagaratnam P, Schmidt B, Rosenqvist M, Nielsen-Kudsk JE, Ibrahim R et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: Opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 2014; 16:626-630.
Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C. EHRA/ EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014; 16:1397-1416.
Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. J Am Coll Cardiol 2014; 64:1-12.
Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009; 374:534-542.
Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013; 127:720-729.
Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: A randomized clinical trial. JAMA 2014; 312:1988-1998.
Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015; 65:2614-2623.
Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: The ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013; 61:2551-2556.
Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C et al. Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: Implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention 2016; 11:1188-1194.
Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M et al. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: Influence of hospital volume. Circ Arrhythm Electrophysiol 2015; 8:42-48.
Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C. Left atrial appendage closure-indications, techniques, and outcomes: Results of the European Heart Rhythm Association Survey. Europace 2015; 17:642-646.
Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: Results from the U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014; 64:565-572.
Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: Peri-procedural outcomes from the EWOLUTION registry. Eur Heart J; doi:10.1093/ eurheartj/ehv730. Published online ahead of print27 January 2016.
Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313:824-836.
Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: Final results of the PRAGUE-12 randomized multicentre study. Eur Heart J 2012; 33:2644-2652.
Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH et al. Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293.
Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: A meta-analysis. Eur J Cardiothorac Surg 2015; 47:847-854.
Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol 2013; 29:1443-1447.
Aryana A, Singh SK, Singh SM, GearoidO'Neill P, Bowers MR, Allen SL et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm 2015; 12:1431-1437.
Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P et al. CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; 372:1399-1409.
Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann Cardiothorac Surg 2014; 3:45-54.
Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): A 2-center randomized clinical trial. Circulation 2012; 125: 23-30.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke 2001; 32:2559-2566.
Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: A systematic review and meta-analysis. Lancet Neurol 2007; 6: 1063-1072.
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E et al. Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet 2014; 384:1929-1935.
Diener HC, Stanford S, Abdul-Rahim A, Christensen L, Hougaard KD, Bakhai A et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother 2014; 14: 1019-1028.
Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke 2014; 9: 627-632.
Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012; 307:2600-2608.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520.
Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Metaanalysis. JAMA 2015; 314:1832-1843.
Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: A meta-analysis of randomized controlled trials. Stroke 2007; 38:423-430.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15:625-651.
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-1163.
Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A et al. ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11:315-322.
Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L et al. ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11:503-511.
Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: A systematic review and metaanalysis of randomized controlled trials. Stroke 2012; 43:3298-3304.
Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?. Thromb Haemost 2014; 111:14-18.
Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015; 132:517-525.
Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967-973.
Yung D, Kapral MK, Asllani E, Fang J, Lee DS. Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: The Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol 2012; 28:33-39.
Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: A systematic review of randomized and observational studies. Europace 2013; 15:787-797.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC et al. ROCKET AF Investigators. Factors associated with major bleeding events: Insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014; 63:891-900.
Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: Population based retrospective cohort study. BMJ 2015; 350:h1585.
Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study. BMJ 2015; 350:h1857.
Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Sj€alander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology 2016; 1:172-180.
Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009; 7:159-166.
Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Am J Med 2014; 127:972-978.
Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A et al. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10:1687-1695.
International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008.
Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C et al. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol Ther 2015; 20:387-394.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015; 373:823-833.
Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64:1128-1139.
Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: A critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J; doi:10.1093/eurheartj/ehv676. Published online ahead of print 24 December 2015.
Parry-Jones AR, Di Napoli M, Goldstein JN, Schreuder FH, Tetri S, Tatlisumak T et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol 2015; 78:54-62.
Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385:2077-2087.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373:2413-2424.
Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: Current status and future potential. Arterioscler Thromb Vasc Biol 2015; 35: 1736-1745.
Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015; 351:h5876.
Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: A Cochrane Systematic review. J Hum Hypertens 2005; 19:185-196.
Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015; 132:194-204.
Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51:818-825.
Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170:1433-1441.
Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. Circulation 2012; 126:1185-1193.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541-2619.
Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P et al. American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S-668S.
Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marin F, Bhatt DL. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Haemost 2014; 112:1080-1087.
Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-analysis. Eur Heart J 2013; 34:1670-1680.
Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35:3155-3179.
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61:2060-2066.
Jackson LR II, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv 2015; 8:1880-1889.
Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381:1107-1115.
Braun O€O, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res 2015; 135:26-30.
Nikolaidou T, Channer KS. Chronic atrial fibrillation: A systematic review of medical heart rate control management. Postgrad Med J 2009; 85: 303-312.
Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin 2004; 22:35-45.
Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR et al. The evidence regarding the drugs used for ventricular rate control. In. J Fam Practice 2000; 49:47-59.
Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: Intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997; 29:135-140.
Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009; 37:2174-2179; quiz 2180.
Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J 1998; 135:739-747.
Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013; 20:222-230.
Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012; 125:945-957.
Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998; 89:38-46.
Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases lateonset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83:52-60.
Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594-598.
Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29: 1149-1153.
Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995; 16:521-528.
National Institute for Health and Care Excellence (NICE) guidelines. Atrial fibrillation: Management. http://www.nice.org.uk/guidance/ cg180/ (5 May 2016).
Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG et al. Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of b blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta-analysis. BMJ 2016; 353:i1855.
Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013; 111:225-230.
Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with betablockers in patients with permanent atrial fibrillation. Eur Heart J 2014; 35:517-524.
Goldberger ZD, Alexander GC. Digitalis use in contemporary clinical practice: Refitting the foxglove. JAMA Intern Med 2014; 174:151-154.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533.
Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006; 114: 397-403.
Ziff OJ, Kotecha D. Digoxin: The good and the bad. Trends in Cardiovascular Medicine; doi:10.1016/j.tcm.2016.03.011. Published online ahead of print 30 March 2016.
Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: Findings from the TREAT-AF study. J Am Coll Cardiol 2014; 64:660-668.
Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H. Digoxin and mortality in atrial fibrillation: A prospective cohort study. Eur J Clin Pharmacol 2007; 63:959-971.
Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 2013; 34:1481-1488.
Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensitymatched analysis of the AFFIRM trial. Eur Heart J 2013; 34:1489-1497.
Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan C et al. Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open 2012; 2:e000888.
Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, Garcia-Dominguez G et al. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. Int J Clin Pract 2011; 65:1250-1258.
Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD et al. ORBIT-AF Investigators. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol 2015; 65:2691-2698.
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 2003; 42:1944-1951.
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304-310.
Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995; 75:88-90.
Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989; 13:1-6.
Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K. Rate control and quality of life in patients with permanent atrial fibrillation: The Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J 2006; 70:965-970.
ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF). https://clinicaltrials.gov/ct2/show/NCT02391337 (5 May 2016).
Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM et al. RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363-1373.
Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG et al. RACE II Investigators. The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011; 58:1795-1803.
Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE. RACE and AFFIRM Investigators. Does intensity of ratecontrol influence outcome in atrial fibrillation?. An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006; 8:935-942.
Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: Long term survival and predictors of permanent atrial fibrillation. Heart 2003; 89:1035-1038.
Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M. Ablate and pace strategy for atrial fibrillation: Long-term outcome of AIRCRAFT trial. Europace 2007; 9:498-505.
Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997; 20:343-348.
Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 2013; 10:696-701.
Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: A metaanalysis and systematic review. Circ Arrhythm Electrophysiol 2012; 5: 68-76.
Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly patients: Pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther 2007; 81:284-287.
Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation : A metaanalysis. Circulation 2000; 101:1138-1144.
Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344:1043-1051.
Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation?. A systematic review and meta-analysis. Curr Cardiol Rep 2013; 15:330.
Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006; 114:18-25.
Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34:2281-2329.
Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: A meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012; 14: 661-667.
Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: The effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988; 9: 777-781.
Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. Heart Rhythm 2014; 11: 1543-1550.
Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: Randomized crossover study. Int J Cardiol 1995; 52:167-174.
Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: An updated comprehensive review and meta-analysis. PACE 2013; 36:122-133.
de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: A meta-analysis. Arch Intern Med 2005; 165:258-262.
Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5:CD005049.
Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913-920.
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667-2677.
Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987-999.
Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380: 238-246.
Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012; 367:1587-1595.
Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A et al. ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 2010; 303:333-340.
Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P et al. Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: A European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014; 35:1466-1478.
Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668-678.
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833.
Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P. Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126:476-486.
Kong MH, Shaw LK, O'Connor C, Califf RM, Blazing MA, Al-Khatib SM. Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?. Ann Noninvasive Electrocardiol 2010; 15: 209-217.
Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. Evid Based Med 2014; 19:222-223.
ClinicalTrials.gov. Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA). https://clinicaltrials.gov/ct2/show/ NCT00911508 (5 May 2016).
Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 87:121-128.
Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2003; 41:255-262.
Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: A meta-analysis. Arch Intern Med 2003; 163:777-785.
Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89: 239-248.
Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V et al. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: A randomized, digoxin-controlled trial. Am Heart J 2004; 147:E3.
Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006; 151:863.e1-6.
Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518-1525.
Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:652-659.
Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57:313-321.
Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012; 26:167-179
Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997; 29:385-390.
Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of stable atrial fibrillation in the emergency department: A population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management. Cardiology 2009; 112:270-278.
Chen WS, Gao BR, Chen WQ, Li ZZ, Xu ZY, Zhang YH et al. Comparison of pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac valve replacement: A prospective randomized trial. J Int Med Res 2013; 41:1067-1073.
Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T. Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: Results of the German RHYTHM-AF Study. Clin Res Cardiol 2013; 102:713-723.
Cristoni L, Tampieri A, Mucci F, Iannone P, Venturi A, Cavazza M. Cardioversion of acute atrial fibrillation in the short observation unit: Comparison of a protocol focused on electrical cardioversion with simple antiarrhythmic treatment. Emerg Med J 2011; 28:932-937.
Bellone A, Etteri M, Vettorello M, Bonetti C, Clerici D, Gini G et al. Cardioversion of acute atrial fibrillation in the emergency department: A prospective randomised trial. Emerg Med J 2012; 29:188-191.
Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol 2014; 172:588-594.
Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol 2014; 113:480-484.
Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004; 25:1318-1324.
Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996; 94:1613-1621.
Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013; 166:147-151.
Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: Evidence in support of the ESC Guidelines. Europace 2014; 16:162-173.
Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: A randomized controlled trial at the emergency department. Europace; doi:10.1093/europace/ euw052. Published online ahead of print 22 March 2016.
Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454.
Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-inthe-pocket" approach. N Engl J Med 2004; 351:2384-2391.
Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Systematic review and cost-effectiveness evaluation of 'pill-in-thepocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 2010; 14:iii-iv, 1-75.
Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001; 37:542-547.
Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997; 79:418-423.
Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial fibrillation-A review. Can J Cardiol 1997; 13:839-842.
Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 2005; 59:1395-1400.
Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ et al. Transthoracic cardioversion of atrial fibrillation: Comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000; 101:1282-1287.
Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: A randomised trial. Lancet 2002; 360:1275-1279.
Kirchhof P, Monnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005; 26:1292-1297.
Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart 2015; 101:1526-1530.
Alp N, Rahman S, Bell J, Shahi M. Randomised comparison of anterolateral versus antero-posterior paddle positions for DC cardioversion of persistent atrial fibrillation. Int J Cardiol 2000; 75:211-216.
Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: A substudy of the SAFE-T trial. Heart Rhythm 2009; 6:152-155.
Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25:144-150.
Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849-1854.
Mussigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A. Vernakalant-facilitated electrical cardioversion: Comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace 2016; 18:51-56.
Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. J Am Coll Cardiol 1996; 28:700-706.
Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: A randomized double-blind placebo-controlled study. Eur Heart J 2007; 28:1351-1357.
Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ, Bosker HA et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol 2006; 48:1001-1009.
Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: A single-blind, randomized, controlled study. Am Heart J 2000; 140:e12.
De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999; 34:810-814.
The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebocontrolled multicentre trial in 239 patients. Eur Heart J 1997; 18:649-654.
Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H. Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 2002; 66:553-556.
Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F. Thromboembolic complications after cardioversion of acute atrial fibrillation: The FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 2013; 62:1187-1192.
Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 2015; 17:18-23.
Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: A statutory health insurance perspective from Germany. Am J Cardiovasc Drugs 2007; 7:199-217.
Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J et al. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res 2007; 119:27-34.
Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109:997-1003.
Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 2014; 312:647-649.
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35:3346-3355.
Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: A double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35: 3356-3364.
Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77-82.
Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in long QT syndrome: A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009; 54:143-149.
Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4:1250-1259.
Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009; 16:43-48.
Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial. JAMA 2008; 300: 1784-1792.
Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156:527.e1-9.
Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H et al. Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678-2687.
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268-2276.
Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64:785-791.
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412.
Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13:329-345.
Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 1251-1258.
Sirak TE, Sherrid MV. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting. Chest 2008; 133:1243-1246.
Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail 2013; 6:694-702.
Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7-12.
Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104:292-296.
Shamiss Y, Khaykin Y, Oosthuizen R, Tunney D, Sarak B, Beardsall M et al. Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation. Europace 2009; 11: 1448-1455.
Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C et al. The potential for QT prolongation and proarrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47:219-233.
K€a€ab S, Hinterseer M, N€abauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QTsyndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 2003; 24:649-657.
Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: Individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 2010; 106:263-268.
Choy AM, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999; 34:396-401.
Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M et al. Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 2004; 25:1395-1404.
Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol 2012; 59:539-546.
Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K et al. Human electrophysiological and pharmacological properties of XEN-D0101: A novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 2013; 61:408-415.
Loose S, Mueller J, Wettwer E, Knaut M, Ford J, Milnes J. Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation. Front Pharmacol 2014; 5:26.
Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: Ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142:1300-1308.
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93:135-142.
Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non STElevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647-1652.
Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, Karwatowska-Prokopczuk E et al. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: Observations from the MERLIN-TIMI 36 trial. Europace 2015; 17:32-37.
Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A et al, HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol 2015; 8:1048-1056.
Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol 2012; 110:673-677.
Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K et al. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. Angiology 2014; 65:294-297.
Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014; 16:973-979.
De Ferrari GM, Maier LS, Mont L, Schwartz PJ, Simonis G, Leschke M et al. RAFFAELLO Investigators. Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm 2015; 12:872-878.
Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials. Heart 2014; 100:1506-1510.
Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296:1242-1248.
Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention. Europace 2011; 13:610-625.
Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: A randomized, double-blind, placebocontrolled study. J Am Coll Cardiol 2000; 36:139-146.
Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012; 4:Cd008493.
Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH. Preoperative statin therapy in cardiac surgery: A meta-analysis of 90, 000 patients. Eur J Cardiothorac Surg 2014; 45:17-26; discussion 26.
Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016; 374: 1744-1753.
Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW et al. PROSPER Executive. Effect of statins on atrial fibrillation: Collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011; 342:d1250.
Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: Role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal 2014; 20:1268-1285.
Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P et al. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: A randomized, double-blind, multicentre study. Europace 2011; 13: 174-181.
Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA 2010; 304:2363-2372.
Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ et al. OPERA Investigators. Fish oil and postoperative atrial fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012; 308:2001-2011.
Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al. J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13:473-479.
Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J et al. GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: Results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol 2013; 61:463-468.
Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A et al. Effect of combined spironolactone-b-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106:1609-1614.
Ito Y, Yamasaki H, Naruse Y, Yoshida K, Kaneshiro T, Murakoshi N et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol 2013; 111:1012-1018.
Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H et al. EMPHASIS-Hf Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59:1598-1603.
Coll-Vinent B, Sala X, Fernandez C, Bragulat E, Espinosa G, Miro O et al. Sedation for cardioversion in the emergency department: Analysis of effectiveness in four protocols. Ann Emerg Med 2003; 42:767-772.
del Arco C, Martin A, Laguna P, Gargantilla P. Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005; 46:424-430.
Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency department management and 1-year outcomes of patients with atrial flutter. Ann Emerg Med 2011; 57:564-571.e2.
Goldner BG, Baker J, Accordino A, Sabatino L, DiGiulio M, Kalenderian D et al. Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment. Am Heart J 1998; 136:961-964.
Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950-953.
Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni Silveri N. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: Systematic review and meta-analysis. J Clin Pharmacol 2012; 52:1872-1878.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35:3346-3355.
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion. Circulation 2011; 123:131-136.
Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109:1973-1980.
Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350:1210-1216.
Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000; 342:1385-1391.
Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2:349-361.
Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial. J Hypertens 2008; 26:403-411.
Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14:528-606.
Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A et al. Gap-AF-AFNET 1 Investigators. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circ Arrhythm Electrophysiol 2016; 9:e003337.
Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A et al. SARA investigators. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: A multicentre, randomized, controlled trial (SARA study). Eur Heart J 2014; 35:501-507.
Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA et al. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 2015; 8:308-317.
Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol 2015; 8:18-24.
Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T et al. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol 2015; 1:200-209.
Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: Systematic review and meta-analysis. Europace 2015; 17:370-378.
Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J et al. RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): A randomized trial. JAMA 2014; 311:692-700.
Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293:2634-2640.
Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934-941.
Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: A prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27:216-221.
Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: Results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009; 20:22-28.
Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3:32-38.
Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Longterm outcomes of catheter ablation of atrial fibrillation: A systematic review and meta-analysis. J Am Heart Assoc 2013; 2:e004549.
McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S et al. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: A prospective multi-centre randomized controlled trial (the Minimax study). Eur Heart J 2015; 36:1812-1821.
Verma A, Sanders P, Macle L, Deisenhofer I, Morillo CA, Chen J et al. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial-Part II (STAR AF II): Design and rationale. Am Heart J 2012; 164:1-6.e6.
Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A et al. Relationship Between Pulmonary Vein Reconnection and Atrial Fibrillation Recurrence. JACC Clin Electrophysiol; doi:10.1016/j.jacep. 2016.02.003. Published online ahead of print April 2016.
Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P et al. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. Circulation 2015; 132: 1311-1319.
Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck KH, Kuniss M et al. Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: Results from the German Ablation Registry. J Cardiovasc Electrophysiol 2014; 25:1-7.
Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR et al. FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016; 374:2235-2245.
Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R et al. STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372:1812-1822.
Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. Europace 2015; 17:1798-1806.
Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012; 98:48-53.
Providencia R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K, Ahsan S et al. Is There Still a Role for Complex Fractionated Atrial Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and Persistent Atrial Fibrillation?. Meta-Analysis of 1415 Patients. Circ Arrhythm Electrophysiol 2015; 8:1017-1029.
Mohanty S, Gianni C, Mohanty P, Halbfass P, Metz T, Trivedi C et al. Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a Randomized Trial (OASIS). J Am Coll Cardiol; doi:10.1016/j.jacc.2016.04. 015. Published online ahead of print 6 May 2016.
Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S et al. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2014; 7:825-833.
Shah AJ, Pascale P, Miyazaki S, Liu X, Roten L, Derval N et al. Prevalence and types of pitfall in the assessment of mitral isthmus linear conduction block. Circ Arrhythm Electrophysiol 2012; 5:957-967.
Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S et al. ADVICE trial investigators. Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: An international, multicentre, randomised superiority trial. Lancet 2015; 386:672-679.
Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y et al. UNDER-ATP Trial Investigators. Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: The UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial. Eur Heart J 2015; 36:3276-3287.
Berntsen RF, Haland TF, Skardal R, Holm T. Focal impulse and rotor modulation as a stand-alone procedure for treatment of paroxysmal atrial fibrillation. A within-patient controlled study with implanted cardiac monitoring. Heart Rhythm 2016; doi:10.1016/j.hrthm.2016.04.016.
Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: Results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011; 22:163-168.
Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: A systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol 2014; 7:841-852.
Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation 2014; 129:704-710.
Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K et al. Complications of atrial fibrillation ablation in a high-volume center in 1, 000 procedures: Still cause for concern?. J Cardiovasc Electrophysiol 2009; 20:1014-1019.
Deneke T, Jais P, Scaglione M, Schmitt R, L DIB, Christopoulos G et al. Silent cerebral events/lesions related to atrial fibrillation ablation: A clinical review. J Cardiovasc Electrophysiol 2015; 26:455-463.
Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC et al. Complications of catheter ablation of atrial fibrillation: A systematic review. Circ Arrhythm Electrophysiol 2013; 6:1082-1088.
Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al. Delayed cardiac tamponade after radiofrequency catheter ablation of atrial fibrillation: A worldwide report. J Am Coll Cardiol 2011; 58: 2696-2697.
Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 2012; 43:265-270.
Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A et al. Early cerebral thromboembolic complications after radiofrequency catheter ablation of atrial fibrillation: Incidence, characteristics, and risk factors. Heart Rhythm 2014; 11:1934-1940.
Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: Comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 2011; 22:961-968.
Hsu LF, Jais P, Hocini M, Sanders P, Scavee C, Sacher F et al. Incidence and prevention of cardiac tamponade complicating ablation for atrial fibrillation. Pacing Clin Electrophysiol 2005; 28:S106-109.
Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S et al. Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: Results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ Arrhythm Electrophysiol 2014; 7:274-280.
Nair KK, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C et al. The prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter ablation for atrial fibrillation: The Canadian experience. J Interv Card Electrophysiol 2014; 39:139-144.
Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 2012; 59:143-149.
Straube F, Dorwarth U, Schmidt M, Wankerl M, Ebersberger U, Hoffmann E. Comparison of the first and second cryoballoon: Highvolume single-center safety and efficacy analysis. Circ Arrhythm Electrophysiol 2014; 7:293-299.
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation 2014; 129:2638-2644.
Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm 2015; 12:1162-1168.
Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: A meta-analysis of the literature. Europace 2013; 15:1407-1411.
Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63:982-988.
Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014; 16:1137-1144.
Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 2014; 40:33-38.
Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014; 114:577-582.
Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 2015; 115:47-51.
Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ et al. VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36:1805-1811.
Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Am J Cardiol 2016; 117:926-934.
Santarpia G, De Rosa S, Polimeni A, Giampa S, Micieli M, Curcio A. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis. PLoS One 2015; 10:e0126512.
Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: Long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2015; 36:307-314a.
Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010; 55:735-743.
Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013; 10:1272-1277.
Nedios S, Kornej J, Koutalas E, Bertagnolli L, Kosiuk J, Rolf S et al. Left atrial appendage morphology and thromboembolic risk after catheter ablation for atrial fibrillation. Heart Rhythm 2014; 11:2239-2246.
Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: Results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes 2012; 5:171-181.
Gallo C, Battaglia A, Anselmino M, Bianchi F, Grossi S, Nangeroni G et al. Long-term events following atrial fibrillation rate control or transcatheter ablation: A multicenter observational study. J Cardiovasc Med (Hagerstown) 2016; 17:187-193.
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D et al. Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation; doi:10.1161/CIRCULATIONAHA.115.019406. Published online ahead of print 30 March 2016.
Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014; 7:31-38.
MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: A randomised controlled trial. Heart 2011; 97:740-747.
Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK et al. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card Fail 2011; 17:964-970.
Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A. Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2005; 16:1286-1292.
Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): A prospective, multicenter study. JAMA Intern Med 2013; 173:149-156.
Cox JL, Boineau JP, Schuessler RB, Ferguson TB Jr., Cain ME, Lindsay BD et al. Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA 1991; 266:1976-1980.
Cox JL, Schuessler RB, D'Agostino HJ Jr, Stone CM, Chang BC, Cain ME et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991; 101: 569-583.
Stulak JM, Suri RM, Burkhart HM, Daly RC, Dearani JA, Greason KL et al. Surgical ablation for atrial fibrillation for two decades: Are the results of new techniques equivalent to the Cox maze III procedure?. J Thorac Cardiovasc Surg 2014; 147:1478-1486.
Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofrequency ablation for atrial fibrillation during concomitant cardiac surgery?. Interact CardioVasc Thorac Surg 2012; 15:741-748.
Lin Z, Shan ZG, Liao CX, Chen LW. The effect of microwave and bipolar radio-frequency ablation in the surgical treatment of permanent atrial fibrillation during valve surgery. Thorac Cardiovasc Surg 2011; 59:460-464.
McCarthy PM, Kruse J, Shalli S, Ilkhanoff L, Goldberger JJ, Kadish AH et al. Where does atrial fibrillation surgery fail?. Implications for increasing effectiveness of ablation. J Thorac Cardiovasc Surg 2010; 139: 860-867.
Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca M et al. Effectiveness of the maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation 2005; 112:I20-25.
Blomstrom-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: The SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J 2007; 28:2902-2908.
Chevalier P, Leizorovicz A, Maureira P, Carteaux JP, Corbineau H, Caus T et al. Left atrial radiofrequency ablation during mitral valve surgery: A prospective randomized multicentre study (SAFIR). Arch Cardiovasc Dis 2009; 102:769-775.
Deneke T, Khargi K, Grewe PH, Laczkovics A, von Dryander S, Lawo T et al. Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with chronic atrial fibrillation and mitral valve disease. A randomized, prospective trial. Eur Heart J 2002; 23:558-566.
Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG et al. Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: A randomized controlled trial. JAMA 2005; 294:2323-2329.
Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazer H, Kilger E et al. Surgical treatment of permanent atrial fibrillation using microwave energy ablation: A prospective randomized clinical trial. Eur J Cardiothorac Surg 2003; 24:475-480; discussion 480.
Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F et al. Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and rheumatic heart disease: A randomized trial. Eur Heart J 2010; 31:2633-2641.
Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G et al. Surgical ablation for atrial fibrillation in cardiac surgery: A meta-analysis and systematic review. Innovations (Phila) 2010; 5:84-96.
Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: A meta-analysis. J Thorac Cardiovasc Surg 2006; 131: 1029-1035.
Ad N, Henry L, Massimiano P, Pritchard G, Holmes SD. The state of surgical ablation for atrial fibrillation in patients with mitral valve disease. Curr Opin Cardiol 2013; 28:170-180.
Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr, O'Brien SM et al. Atrial fibrillation correction surgery: Lessons from the Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg 2008; 85:909-914.
Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts the success of radiofrequency maze procedure for permanent atrial fibrillation in patients undergoing concomitant valvular surgery. Chest 2004; 125:2129-2134.
Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the success of maze surgery for atrial fibrillation?. Interact CardioVasc Thorac Surg 2011; 13:332-338.
Chaiyaroj S, Ngarmukos T, Lertsithichai P. Predictors of sinus rhythm after radiofrequency maze and mitral valve surgery. Asian Cardiovasc Thorac Ann 2008; 16:292-297.
Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL et al. Surgery for permanent atrial fibrillation: Impact of patient factors and lesion set. Ann Thorac Surg 2006; 82:502-513; discussion 513-504.
Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardiothorac Surg 2008; 34:771-775.
Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson G et al. Surgery for paroxysmal atrial fibrillation in the setting of mitral valve disease: A role for pulmonary vein isolation?. Ann Thorac Surg 2006; 81:19-26; discussion 27-18.
Onorati F, Mariscalco G, Rubino AS, Serraino F, Santini F, Musazzi A et al. Impact of lesion sets on mid-term results of surgical ablation procedure for atrial fibrillation. J Am Coll Cardiol 2011; 57:931-940.
Saint LL, Bailey MS, Prasad S, Guthrie TJ, Bell J, Moon MR et al. Cox-Maze IV results for patients with lone atrial fibrillation versus concomitant mitral disease. Ann Thorac Surg 2012; 93:789-794; discussion 794-785.
Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac Cardiovasc Surg 2014; 148:955-961; discussion 962-952.
Edgerton JR, Brinkman WT, Weaver T, Prince SL, Culica D, Herbert MA. Pulmonary vein isolation and autonomic denervation for the management of paroxysmal atrial fibrillation by a minimally invasive surgical approach. J Thorac Cardiovasc Surg 2010; 140:823-828.
McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach to treat atrial fibrillation. J Cardiovasc Electrophysiol 2007; 18:1289-1295.
Castella M, Pereda D, Mestres CA, Gomez F, Quintana E, Mulet J. Thoracoscopic pulmonary vein isolation in patients with atrial fibrillation and failed percutaneous ablation. J Thorac Cardiovasc Surg 2010; 140:633-638.
Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS, Jackman WM et al. Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: First results of a hybrid surgicalelectrophysiological approach for atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4:262-270.
La Meir M, Gelsomino S, Lorusso R, Luca F, Pison L, Parise O et al. The hybrid approach for the surgical treatment of lone atrial fibrillation: One-year results employing a monopolar radiofrequency source. J Cardiothorac Surg 2012; 7:71.
Wang S, Liu L, Zou C. Comparative study of video-assisted thoracoscopic surgery ablation and radiofrequency catheter ablation on treating paroxysmal atrial fibrillation: A randomized, controlled short-term trial. Chin Med J (Engl) 2014; 127:2567-2570.
Phan K, Phan S, Thiagalingam A, Medi C, Yan TD. Thoracoscopic surgical ablation versus catheter ablation for atrial fibrillation. Eur J Cardiothorac Surg 2016; 49:1044-1051.
Hu QM, Li Y, Xu CL, Han J, Zhang HB, Han W. Analysis of risk factors for recurrence after video-assisted pulmonary vein isolation of lone atrial fibrillation-results of 5 years of follow-up. J Thorac Cardiovasc Surg 2014; 148:2174-2180.
Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA. Minimally invasive pulmonary vein isolation and partial autonomic denervation for surgical treatment of atrial fibrillation. Ann Thorac Surg 2008; 86:35-38; discussion 39.
Wang J, Li Y, Shi J, Han J, Xu C, Ma C. Minimally invasive surgical versus catheter ablation for the long-lasting persistent atrial fibrillation. PLoS One 2011; 6:e22122.
Wang JG, Xin M, Han J, Li Y, Luo TG, Wang J et al. Ablation in selective patients with long-standing persistent atrial fibrillation: Medium-term results of the Dallas lesion set. Eur J Cardiothorac Surg 2014; 46:213-220.
Sirak JH, Schwartzman D. Interim results of the 5-box thoracoscopic maze procedure. Ann Thorac Surg 2012; 94:1880-1884.
Kasirajan V, Spradlin EA, Mormando TE, Medina AE, Ovadia P, Schwartzman DS et al. Minimally invasive surgery using bipolar radiofrequency energy is effective treatment for refractory atrial fibrillation. Ann Thorac Surg 2012; 93:1456-1461.
Weimar T, Vosseler M, Czesla M, Boscheinen M, Hemmer WB, Doll KN. Approaching a paradigm shift: Endoscopic ablation of lone atrial fibrillation on the beating heart. Ann Thorac Surg 2012; 94:1886-1892.
La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A et al. Minimally invasive surgical treatment of lone atrial fibrillation: Early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol 2013; 167:1469-1475.
Gelsomino S, Van Breugel HN, Pison L, Parise O, Crijns HJ, Wellens F et al. Hybrid thoracoscopic and transvenous catheter ablation of atrial fibrillation. Eur J Cardiothorac Surg 2014; 45:401-407.
Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012; 60:54-61.
De Maat GE, Van Gelder IC, Rienstra M, Quast AF, Tan ES, Wiesfeld AC et al. Surgical vs. transcatheter pulmonary vein isolation as first invasive treatment in patients with atrial fibrillation: A matched group comparison. Europace 2014; 16:33-39.
Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM 3rd, Schaff HV. Left ventricular dysfunction in atrial fibrillation: Restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 2006; 82:494-501.
Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY et al. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardiabradycardia syndrome?. Pacing Clin Electrophysiol 2014; 37:403-411.
Khaykin Y, Marrouche NF, Martin DO, Saliba W, Schweikert R, Wexman M et al. Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol 2004; 15:784-789.
Ad N, Henry L, Hunt S. Current role for surgery in treatment of lone atrial fibrillation. Semin Thorac Cardiovasc Surg 2012; 24:42-50.
Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL. The cox-maze procedure for lone atrial fibrillation: A single-center experience over 2 decades. Circ Arrhythm Electrophysiol 2012; 5:8-14.
Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypass surgery?. J Thorac Cardiovasc Surg 2012; 143: 936-944.
Prakash A, Saksena S, Krol RB, Filipecki A, Philip G. Catheter ablation of inducible atrial flutter, in combination with atrial pacing and antiarrhythmic drugs (hybrid therapy) improves rhythm control in patients with refractory atrial fibrillation. J Interv Card Electrophysiol 2002; 6:165-172.
Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: Electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol 1999; 10:1180-1187.
Stabile G, De Simone A, Turco P, La Rocca V, Nocerino P, Astarita C et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 2001; 37:1639-1644.
Anastasio N, Frankel DS, Deyell MW, Zado E, Gerstenfeld EP, Dixit S et al. Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation. J Interv Card Electrophysiol 2012; 35:57-61.
Garcia Seara J, Raposeiras Roubin S, Gude Sampedro F, Balboa Barreiro V, Martinez Sande JL, Rodriguez Manero M. Failure of hybrid therapy for the prevention of long-term recurrence of atrial fibrillation. Int J Cardiol 2014; 176:74-79.
Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ et al. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol 2002; 40:1140-1150; discussion 1151-1142.
Wharton JM, Sorrentino RA, Campbell P, Gonzalez-Zuelgaray J, Keating E, Curtis A et al. Effect of pacing modality on atrial tachyarrhythmia recurrence in the tachycardia-bradycardia syndrome: Preliminary results of the Pacemaker Atrial Tachycardia Trial. Circulation 1998; 98:I-494.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients: Implications for thromboprophylaxis. J Am Coll Cardiol 2010; 56:827-837.
Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31:822-827.
Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M et al. ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: Expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36:3238-3249.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36:2793-2867.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733-2779.
Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008; 5:704-709.
Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003; 14:1027-1033.
Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J et al. Atrial Arrhythmias in long-QT syndrome under daily life conditions: A nested case control study. J Cardiovasc Electrophysiol 2009; 20: 401-407.
Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92:2929-2934.
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C et al. Genotype-phenotype correlation in the long-QT syndrome: Genespecific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.
Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T et al. Brugada syndrome and supraventricular tachyarrhythmias: A novel association?. J Cardiovasc Electrophysiol 2001; 12:680-685.
Kaufman ES. Mechanisms and clinical management of inherited channelopathies: Long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm 2009; 6:S51-55.
Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442-449.
London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007; 116:2260-2268.
Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118:2260-2268.
Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30-35.
Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R et al. Short QT Syndrome: A familial cause of sudden death. Circulation 2003; 108:965-970.
Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P et al. Short QT syndrome: Clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27:2440-2447.
Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M et al. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007; 116:1569-1576.
Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4:675-678.
Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2007; 18:791-797.
Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan-a tertiary center experience. Clin Cardiol 2007; 30:177-182.
Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D'Alessandro G et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 94:895-900.
Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:301-307.
Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104: 3030-3033.
Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A et al. A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res 2008; 102:1433-1442.
Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: A practical guide for physicians. J Am Coll Cardiol 2013; 61:1945-1948.
Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010; 106:720-722.
Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al. European Society of Cardiology Committee, NASPEHeart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003; 42:1493-1531.
Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ. When should we recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome?. Curr Opin Cardiol 2008; 23:32-37.
Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and electrophysiological study of asymptomatic Wolff-Parkinson-White syndrome]. Ann Cardiol Angeiol (Paris) 2007; 56:237-240.
Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003; 349:1803-1811.
Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: Importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990; 16:1408-1414.
O'Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1991; 14:2028-2034.
Manolis AS, Estes NA III. Supraventricular tachycardia. Mechanisms and therapy. Arch Intern Med 1987; 147:1706-1716.
Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. Intern Emerg Med 2010; 5:421-426.
Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. Heart 2014; 100:465-472.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517-2524.
Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population. Heart 1998; 79:331-336.
Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 19:1009-1014
Di Donna P, Olivotto I, Delcre SD, Caponi D, Scaglione M, Nault I et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression. Europace 2010; 12:347-355.
Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007; 99: 1575-1581.
Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006; 3:275-280.
McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E et al. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace 2011; 13:355-361.
Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S et al. Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. J Am Coll Cardiol 2012; 60:1173-1181.
Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G et al. Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk. J Am Coll Cardiol 2012; 59:1017-1025.
Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E et al. Atrial fibrillation in a large population with Brugada electrocardiographic pattern: Prevalence, management, and correlation with prognosis. Heart Rhythm 2014; 11:259-265.
Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA 2005; 293:447-454.
Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA. Mutations in the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart 2004; 90:1487-1488.
Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013; 15:1389-1406.
Antz M, Weiss C, Volkmer M, Hebe J, Ernst S, Ouyang F. Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 2002; 13:231-236.
Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995; 76:492-494.
Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1996; 27:690-695.
Al-Khatib SM, Arshad A, Balk EM, Das SR, Hsu JC, Joglar JA. Risk stratification for arrhythmic events in patients with asymptomatic preexcitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016; 13:e222-237.
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64: 83-99.
Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. J Am Coll Cardiol 1990; 15:1279-1285.
Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: The cardiovascular health study. Circulation 2008; 118:800-807.
Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E et al. Sport practice and the risk of lone atrial fibrillation: A case-control study. Int J Cardiol 2006; 108:332-337.
Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002; 23:477-482.
Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population?. A systematic review and meta-analysis. Europace 2009; 11:1156-1159.
Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: A prospective study of 309, 540 men and women. Heart 2013; 99:1755-1760.
Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid JP, Saner H. Atrial remodeling, autonomic tone, and lifetime training hours in nonelite athletes. Am J Cardiol 2011; 108:580-585.
Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y et al. Atrial fibrillation promotion by endurance exercise: Demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol 2013; 62:68-77.
Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K. Risk of arrhythmias in 52 755 long-distance cross-country skiers: A cohort study. Eur Heart J 2013; 34:3624-3631.
Biffi A, Maron BJ, Culasso F, Verdile L, Fernando F, Di Giacinto B et al. Patterns of ventricular tachyarrhythmias associated with training, deconditioning and retraining in elite athletes without cardiovascular abnormalities. Am J Cardiol 2011; 107:697-703.
Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace 2010; 12:30-36.
Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L et al. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace 2011; 13:1386-1393.
Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, Delise P et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil 2006; 13:475-484.
Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206-1212.
Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR et al. Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015; 1:284-292.
Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915-2957.
Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130:871-876.
Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; 3:CD002863.
Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 1987; 12:253-291.
Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac arrhythmias in pregnancy: Clinical and therapeutic considerations. Int J Cardiol 2003; 88:129-133.
Joint Formulary Committee. British National Formulary (online). http:// www.medicinescomplete.com (2 December 2014).
Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001; 24:116-130.
Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: Results of a nonrandomized multicenter study. Circulation 2011; 124:1747-1754.
Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal supraventricular tachycardias during pregnancy: A review of the literature. J Obstet Gynaecol Can 2011; 33:17-23.
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S-736S.
Ahlsson AJ, Bodin L, Lundblad OH, Englund AG. Postoperative atrial fibrillation is not correlated to C-reactive protein. Ann Thorac Surg 2007; 83:1332-1337.
Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev 2013; 1: Cd003611.
Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720-1729.
Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL et al. Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: Insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin Cardiol 2014; 37:7-13.
Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: Efficacy of prophylactic betablockers in the modern era: A meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol 2013; 18:58-68.
Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of postoperative atrial fibrillation and its complications after cardiac surgery: A meta-analysis. Eur Heart J 2006; 27:2846-2857.
Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone for prevention of postoperative atrial fibrillation after cardiac surgery: A network regression meta-analysis. Pacing Clin Electrophysiol 2013; 36:1017-1023.
Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J 2012; 42:1078-1087.
Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: Systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013; 28:7-18.
Zheng H, Xue S, Hu ZL, Shan JG, Yang WG. The use of statins to prevent postoperative atrial fibrillation after coronary artery bypass grafting: A meta-analysis of 12 studies. J Cardiovasc Pharmacol 2014; 64: 285-292.
Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q et al. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016; 374: 1744-1753.
Cook RC, Yamashita MH, Kearns M, Ramanathan K, Gin K, Humphries KH. Prophylactic magnesium does not prevent atrial fibrillation after cardiac surgery: A meta-analysis. Ann Thorac Surg 2013; 95:533-541.
De Oliveira GS Jr, Knautz JS, Sherwani S, McCarthy RJ. Systemic magnesium to reduce postoperative arrhythmias after coronary artery bypass graft surgery: A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2012; 26:643-650.
Costanzo S, di Niro V, Di Castelnuovo A, Gianfagna F, Donati MB, de Gaetano G. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: An updated meta-analysis. J Thorac Cardiovasc Surg 2013; 146:906-911.
Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA et al. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol 2011; 108:851-856.
Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?. Europace 2010; 12:356-363.
Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: Updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2013; 2:e005033.
Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E et al. A randomized controlled trial to prevent postoperative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013; 62:1457-1465.
Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: A randomized, doubleblind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010; 3:46-53.
Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS et al. Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. J Am Heart Assoc 2013; 2: E000397.
Xin W, Wei W, Lin Z, Zhang X, Yang H, Zhang T et al. Fish oil and atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. PLoS One 2013; 8:e72913.
Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for the prevention of atrial fibrillation after cardiac surgery: An updated meta-analysis of randomized controlled trials. J Cardiol 2014; 63:53-59.
Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A et al. COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: The COPPS-2 randomized clinical trial. JAMA 2014; 312:1016-1023.
Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: A metaanalysis of randomized double-blind trials. J Cardiothorac Vasc Anesth 2011; 25:156-165.
Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid administration associated with a reduced incidence of postoperative atrial fibrillation in adult cardiac surgery?. Interact CardioVasc Thorac Surg 2014; 18:225-229.
Kaleda VI, McCormack DJ, Shipolini AR. Does posterior pericardiotomy reduce the incidence of atrial fibrillation after coronary artery bypass grafting surgery?. Interact CardioVasc Thorac Surg 2012; 14:384-389.
Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30:852-872.
LaPar DJ, Speir AM, Crosby IK, Fonner E Jr, Brown M, Rich JB et al. Investigators for the Virginia Cardiac Surgery Quality Initiative. Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 2014; 98:527-533; discussion 533.
Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19, 497 patients). Am J Cardiol 2012; 109:219-225.
Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014; 312:616-622.
Ahlsson A, Bodin L, Fengsrud E, Englund A. Patients with postoperative atrial fibrillation have a doubled cardiovascular mortality. Scand Cardiovasc J 2009; 43:330-336.
Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010; 37:1353-1359.
Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008; 118:1612-1618.
Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004; 43:742-748.
Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: A systematic review and meta-analysis. Eur J Cardiothorac Surg 2015; 48:817-824.
El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 2010; 55:1370-1376.
Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the management of postoperative atrial fibrillation. Clin Lab Med 2014; 34: 537-561.
Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. Scand Cardiovasc J Suppl 2013; 47:2-10.
Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME et al. CTSN. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med 2016; 374:1911-1921.
Triedman JK. Arrhythmias in adults with congenital heart disease. Heart 2002; 87:383-389.
Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman PA et al. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease. Int J Cardiol 2012; 154:270-274.
Greason KL, Dearani JA, Theodoro DA, Porter CB, Warnes CA, Danielson GK. Surgical management of atrial tachyarrhythmias associated with congenital cardiac anomalies: Mayo Clinic experience. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2003; 6:59-71.
Payne L, Zeigler VL, Gillette PC. Acute cardiac arrhythmias following surgery for congenital heart disease: Mechanisms, diagnostic tools, and management. Crit Care Nurs Clin North Am 2011; 23:255-272.
Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ et al. Sudden cardiac death in adult congenital heart disease. Circulation 2012; 126:1944-1954.
Jensen AS, Idorn L, Norager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with congenital heart disease: The who, the when and the how?. Heart 2014; 101:424-429.
Fujita S, Takahashi K, Takeuchi D, Manaka T, Shoda M, Hagiwara N et al. Management of late atrial tachyarrhythmia long after Fontan operation. J Cardiol 2009; 53:410-416.
Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 1994; 24:1365-1370.
Nagao K, Tsuchihashi K, Tanaka S, Iimura O. [Studies on atrial arrhythmias in atrial septal defect. The influences of aging on atrial fibrillation]. Nihon Ronen Igakkai Zasshi 1995; 32:27-32.
Giamberti A, Chessa M, Abella R, Butera G, Negura D, Foresti S et al. Surgical treatment of arrhythmias in adults with congenital heart defects. Int J Cardiol 2008; 129:37-41.
Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur Heart J 2003; 24: 190-197.
Yamada T, McElderry HT, Muto M, Murakami Y, Kay GN. Pulmonary vein isolation in patients with paroxysmal atrial fibrillation after direct suture closure of congenital atrial septal defect. Circ J 2007; 71: 1989-1992.
Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, Paelinck B, Morissens M. The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. Int J Cardiol 2011; 152:192-195.
de Salle P, Goenen M, Lecron J, Jaumin P, Tremouroux J. [Rhythm disorders occurring after surgical closure of the interatrial communication]. Acta Cardiol 1975; 30:239-249.
Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A et al. Very long-term results of electroanatomic-guided radiofrequency ablation of atrial arrhythmias in patients with surgically corrected atrial septal defect. Europace 2014; 16:1800-1807.
Kanter RJ, Garson A Jr. Atrial arrhythmias during chronic follow-up of surgery for complex congenital heart disease. Pacing Clin Electrophysiol 1997; 20:502-511.
Porter CJ, Garson A. Incidence and management of dysrhythmias after Fontan procedure. Herz 1993; 18:318-327.
Gelatt M, Hamilton RM, McCrindle BW, Gow RM, Williams WG, Trusler GA. Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol 1994; 24:1735-1741.
Peters NS, Somerville J. Arrhythmias after the Fontan procedure. Br Heart J 1992; 68:199-204.
Kwak JG, Kim WH, Lee JR, Kim YJ. Surgical therapy of arrhythmias in single-ventricle patients undergoing Fontan or Fontan conversion. J Card Surg 2009; 24:738-741.
Backer CL, Tsao S, Deal BJ, Mavroudis C. Maze procedure in single ventricle patients. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2008; 11:44-48.
Deal BJ, Mavroudis C, Backer CL. The role of concomitant arrhythmia surgery in patients undergoing repair of congenital heart disease. Pacing Clin Electrophysiol 2008; 31:S13-16.
Gandhi SK. Atrial arrhythmia surgery in congenital heart disease. J Interv Card Electrophysiol 2007; 20:119-125.
Correa R, Sherwin ED, Kovach J, Mah DY, Alexander ME, Cecchin F et al. Mechanism and ablation of arrhythmia following total cavopulmonary connection. Circ Arrhythm Electrophysiol 2015; 8:318-325.
Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon FP, Kay J et al. Alliance for Adult Research in Congenital Cardiology. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: A multiinstitutional study. Circulation 2010; 122:868-875.
Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure for atrial fibrillation associated with atrial septal defect. Circulation 1998; 98:II399-402.
Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the maze procedure for atrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg 2013; 46:98-103.
Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the Cox-maze procedure in congenital heart disease. Congenit Heart Dis 2013; 8:434-439.
Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in congenital heart disease: Evolving solutions for complex hearts. Circ Arrhythm Electrophysiol 2013; 6:1032-1040.
Wellens HJ. Contemporary management of atrial flutter. Circulation 2002; 106:649-652.
Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L et al. Long term follow up of radiofrequency catheter ablation of atrial flutter: Clinical course and predictors of atrial fibrillation occurrence. Heart 2004; 90:59-63.
Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM, Manero MR et al. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter. Clin Res Cardiol 2014; 103:543-552.
Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T et al. Risk of atrial fibrillation after atrial flutter ablation: Impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol 2014; 25:813-820.
Bronis K, Metaxa S, Koulouris S, Manolis AS. Vernakalant: Review of a novel atrial selective antiarrhythmic agent and its place in current treatment of atrial fibrillation. Hosp Chronicles 2012; 7:171-181.
Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation. J Am Board Fam Med 2011; 24: 86-92.
Reisinger J, Gstrein C, Winter T, Zeindlhofer E, Hollinger K, Mori M et al. Optimization of initial energy for cardioversion of atrial tachyarrhythmias with biphasic shocks. Am J Emerg Med 2010; 28:159-165.
Pinski SL, Sgarbossa EB, Ching E, Trohman RG. A comparison of 50-J versus 100-J shocks for direct-current cardioversion of atrial flutter. Am Heart J 1999; 137:439-442.
Manolis AS, Dragazis I, Kapelakis I, Papadimitriou P, Sakellaris N. Transesophageal overdrive pacing: A simple and versatile tool. Hosp Chronicles 2013; 8:143-145.
Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104:671-677.
Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA et al. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J 2003; 24:956-962.
Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation after typical atrial flutter ablation: A long-term follow-up. J Cardiovasc Med (Hagerstown) 2011; 12:110-115.
Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter. PLoS One 2014; 9: E100509.
Esato M, Hindricks G, Sommer P, Arya A, Gaspar T, Bode K et al. Colorcoded three-dimensional entrainment mapping for analysis and treatment of atrial macroreentrant tachycardia. Heart Rhythm 2009; 6: 349-358.
Huo Y, Schoenbauer R, Richter S, Rolf S, Sommer P, Arya A et al. Atrial Arrhythmias Following Surgical AF Ablation: Electrophysiological Findings, Ablation Strategies, and Clinical Outcome. J Cardiovasc Electrophysiol 2014; 25:725-738.
Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001.
Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002; 288:1775-1779.
Hibbard JH, Greene J. What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs. Health Aff (Millwood) 2013; 32:207-214.
McCabe PJ. Self-management of atrial fibrillation: A new frontier for nursing research. Prog Cardiovasc Nurs 2008; 23:37-40.
Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: The West Birmingham Atrial Fibrillation Project. Stroke 2002; 33: 238-242.
Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; 6:Cd008600.
Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. PLoS One 2013; 8:e74037.
Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010; 10:21.
Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP et al. Warfarin knowledge in patients with atrial fibrillation: Implications for safety, efficacy, and education strategies. Cardiology 2010; 116:61-69.
Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE. Atrial Fibrillation AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010; 12:626-633.
Hendriks JM, Crijns HJ, Tieleman RG, Vrijhoef HJ. The atrial fibrillation knowledge scale: Development, validation and results. Int J Cardiol 2013; 168:1422-1428.
McCabe PJ. What patients want and need to know about atrial fibrillation. J Multidiscip Healthc 2011; 4:413-419.
Lorig KR, Holman H. Self-management education: History, definition, outcomes, and mechanisms. Ann Behav Med 2003; 26:1-7.
Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM et al. Shared decision making: Really putting patients at the centre of healthcare. BMJ 2012; 344:e256.
Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014; 1:CD001431.
Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P et al. Shared decision making: A model for clinical practice. J Gen Intern Med 2012; 27:1361-1367.
Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B et al. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm 2015; 12:e5-e29.
van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC et al. APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulationassociated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): Study protocol for a randomised controlled trial. Trials 2015; 16:393.
Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE. Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: The FinCV study. Europace 2013; 15:1432-1435.
Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm?. Effects of prompt cardioversion on the frequency and persistence of recurrent atrial fibrillation. Card Electrophysiol Rev 2003; 7:359-365.
Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: A rationale for early restoration and maintenance of sinus rhythm. Europace 2006; 8:943-949.
Liu ZJ, Fu WG, Guo ZY, Shen LG, Shi ZY, Li JH. Updated systematic review and meta-analysis of randomized clinical trials comparing carotid artery stenting and carotid endarterectomy in the treatment of carotid stenosis. Ann Vasc Surg 2012; 26:576-590.
Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE et al. ASA and Carotid Endarterectomy (ACE) trial collaborators. Lowdose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. Lancet 1999; 353: 2179-2184.
Watanabe M, Chaudhry SA, Adil MM, Alqadri SL, Majidi S, Semaan E. The effect of atrial fibrillation on outcomes in patients undergoing carotid endarterectomy or stent placement in general practice. J Vasc Surg 2015; 61:927-932.
Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR et al. ROCHET AF Steering Committee & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014; 35:3377-3385.
Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D et al. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: The Loire Valley Atrial Fibrillation Project. Eur Heart J 2015; 36: 1822-1830.
Breithardt G, Baumgartner H. Valvular heart disease among nonvalvular atrial fibrillation: A misnomer, in search of a new term. Eur Heart J 2015; 36:1794-1797.
Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg 2005; 130:797-802.
Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg 2008; 136: 521-522.
Salzberg SP, Plass A, Emmert MY, Desbiolles L, Alkadhi H, Grunenfelder J. Left atrial appendage clip occlusion: Early clinical results. J Thorac Cardiovasc Surg 2010; 139:1269-1274.
Papworth Hospital NHS Foundation Trust. A randomised controlled trial to investigate the clinical and cost effectiveness of adding an ablation device-based maze procedure as a routine adjunct to elective cardiac surgery for patients with pre-existing atrial fibrillation. http:// www.isrctn.com/ISRCTN82731440 (5 May 2016).
Amit G, Nyong J, Morillo CA, Casas JP, Adler AJ, Owolabi OO, Perel P, Prieto-Merino D, Lambiase P. Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillation. Cochrane Database of Systematic Reviews 2016; 8: CD012088. DOI: 10.1002/ 14651858.CD012088.pub2.
Huffman MD, Karmali KN, Berendsen MA, Andrei A-C, Kruse J, McCarthy PM, Malaisrie CS. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database of Systematic Reviews 2016; 8: CD011814. DOI: 10.1002/14651858. CD011814.pub2.
Allen V, Banerjee A, SHah AD, Patel, R, Denaxas S, Casas J-P, Hemingway H. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and acros primary and secondary care. Heart, http://dx.doi.org/10.1136/heartjnl-2016-309910.
Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J 2016; 10.1093/eurheartj/ehw260.
